Anke Biotechnology Gets Marketing Approval for Atosiban Acetate Injection

VISEN Pharmaceuticals (HKG:2561) launched its initial public offering in Hong Kong Thursday, seeking to raise up to HK$745.3 million from the deal.

The biopharmaceutical company is offering up to 9,900,000 shares expected to be priced between HK$68.44 and HK$75.28 per share, according to a Thursday filing with the Hong Kong bourse.

VISEN Pharmaceuticals expects to determine the IPO price on March 19 and disclose allocation results on March 20. Shares will begin trading on the stock exchange on March 21.

The biopharmaceutical company intends to use the proceeds to fund the biologics license application and research and development of its imported and locally-manufactured lonapegsomatropin core product for pediatric growth hormone deficiency, fund the open-label extension of its palopegteriparatide for chronic hyperparathyroidism and navepegritide for achondroplasia, and for working capital.

VISEN Pharmaceuticals attracted Anhui Anke Biotechnology subsidiary AnkeBio (HongKong), Suzhou Harvest International, Vivo Capital, WuXi Biologics (Cayman) wholly-owned entity WuXi Biologics HealthCare Venture, and Reynold Lemkins Group (Asia), as cornerstone investors.

Morgan Stanley Asia, Jefferies Hong Kong, CLSA, Futu Securities International (Hong Kong), Guoyuan Securities Brokerage (Hong Kong), Soochow Securities International Brokerage, Patrons Securities, and Ruibang Securities, are the joint bookrunners and lead managers of the IPO.

VISEN Pharmaceuticals (HKG:2561) launched its initial public offering in Hong Kong Thursday, seeking to raise up to HK$745.3 million from the deal.

The biopharmaceutical company is offering up to 9,900,000 shares expected to be priced between HK$68.44 and HK$75.28 per share, according to a Thursday filing with the Hong Kong bourse.

VISEN Pharmaceuticals expects to determine the IPO price on March 19 and disclose allocation results on March 20. Shares will begin trading on the stock exchange on March 21.

The biopharmaceutical company intends to use the proceeds to fund the biologics license application and research and development of its imported and locally-manufactured lonapegsomatropin core product for pediatric growth hormone deficiency, fund the open-label extension of its palopegteriparatide for chronic hyperparathyroidism and navepegritide for achondroplasia, and for working capital.

VISEN Pharmaceuticals attracted Anhui Anke Biotechnology subsidiary AnkeBio (HongKong), Suzhou Harvest International, Vivo Capital, WuXi Biologics (Cayman) wholly-owned entity WuXi Biologics HealthCare Venture, and Reynold Lemkins Group (Asia), as cornerstone investors.

Morgan Stanley Asia, Jefferies Hong Kong, CLSA, Futu Securities International (Hong Kong), Guoyuan Securities Brokerage (Hong Kong), Soochow Securities International Brokerage, Patrons Securities, and Ruibang Securities, are the joint bookrunners and lead managers of the IPO.

Anhui Anke Biotechnology received approval from the Chinese drug administration to conduct clinical trials into a growth hormone drug, according to a Shenzhen Stock Exchange filing on Thursday.

The injection will be tested in babies considered small-for-gestational-age (SGA), a disease that affects infants' growth and development, the biotech company said.

The company's shares closed 3% higher on Friday.

Anhui Anke Biotechnology received approval from the Chinese drug administration to conduct clinical trials into a growth hormone drug, according to a Shenzhen Stock Exchange filing on Thursday.

The injection will be tested in babies considered small-for-gestational-age (SGA), a disease that affects infants' growth and development, the biotech company said.

The company's shares closed 3% higher on Friday.